MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 563663 | Name: URB524

Description:

WARNING: This product is for research use only, not for human or veterinary use.

URB524 is a FAAH inhibitor.

Chemical Structure

URB524
URB524
CAS#546141-07-5

Theoretical Analysis

MedKoo Cat#: 563663

Name: URB524

CAS#: 546141-07-5

Chemical Formula: C19H21NO2

Exact Mass: 295.1572

Molecular Weight: 295.38

Elemental Analysis: C, 77.26; H, 7.17; N, 4.74; O, 10.83

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
URB524; URB-524; URB 524;
IUPAC/Chemical Name
(3-Phenylphenyl) N-cyclohexylcarbamate
InChi Key
KGKDDSYRBQOMLE-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H21NO2/c21-19(20-17-11-5-2-6-12-17)22-18-13-7-10-16(14-18)15-8-3-1-4-9-15/h1,3-4,7-10,13-14,17H,2,5-6,11-12H2,(H,20,21)
SMILES Code
O=C(OC1=CC=CC(C2=CC=CC=C2)=C1)NC3CCCCC3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 295.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Chudyk EI, Dyguda-Kazimierowicz E, Langner KM, Sokalski WA, Lodola A, Mor M, Sirirak J, Mulholland AJ. Nonempirical energetic analysis of reactivity and covalent inhibition of fatty acid amide hydrolase. J Phys Chem B. 2013 Jun 6;117(22):6656-66. doi: 10.1021/jp401834v. Epub 2013 May 28. PubMed PMID: 23654226. 2: Lodola A, Capoferri L, Rivara S, Chudyk E, Sirirak J, Dyguda-Kazimierowicz E, Andrzej Sokalski W, Mileni M, Tarzia G, Piomelli D, Mor M, Mulholland AJ. Understanding the role of carbamate reactivity in fatty acid amide hydrolase inhibition by QM/MM mechanistic modelling. Chem Commun (Camb). 2011 Mar 7;47(9):2517-9. doi: 10.1039/c0cc04937a. Epub 2011 Jan 14. PubMed PMID: 21240393. 3: Clapper JR, Vacondio F, King AR, Duranti A, Tontini A, Silva C, Sanchini S, Tarzia G, Mor M, Piomelli D. A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo. ChemMedChem. 2009 Sep;4(9):1505-13. doi: 10.1002/cmdc.200900210. PubMed PMID: 19637155; PubMed Central PMCID: PMC3016090. 4: Lodola A, Mor M, Sirirak J, Mulholland AJ. Insights into the mechanism and inhibition of fatty acid amide hydrolase from quantum mechanics/molecular mechanics (QM/MM) modelling. Biochem Soc Trans. 2009 Apr;37(Pt 2):363-7. doi: 10.1042/BST0370363. Review. PubMed PMID: 19290863. 5: Mor M, Lodola A, Rivara S, Vacondio F, Duranti A, Tontini A, Sanchini S, Piersanti G, Clapper JR, King AR, Tarzia G, Piomelli D. Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates. J Med Chem. 2008 Jun 26;51(12):3487-98. doi: 10.1021/jm701631z. Epub 2008 May 29. Erratum in: J Med Chem. 2009 Jan 8;52(1):224. PubMed PMID: 18507372; PubMed Central PMCID: PMC3744893. 6: Lodola A, Mor M, Rivara S, Christov C, Tarzia G, Piomelli D, Mulholland AJ. Identification of productive inhibitor binding orientation in fatty acid amide hydrolase (FAAH) by QM/MM mechanistic modelling. Chem Commun (Camb). 2008 Jan 14;(2):214-6. Epub 2007 Oct 19. PubMed PMID: 18092091. 7: Tarzia G, Duranti A, Gatti G, Piersanti G, Tontini A, Rivara S, Lodola A, Plazzi PV, Mor M, Kathuria S, Piomelli D. Synthesis and structure-activity relationships of FAAH inhibitors: cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring. ChemMedChem. 2006 Jan;1(1):130-9. PubMed PMID: 16892344. 8: Mor M, Rivara S, Lodola A, Plazzi PV, Tarzia G, Duranti A, Tontini A, Piersanti G, Kathuria S, Piomelli D. Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem. 2004 Oct 7;47(21):4998-5008. PubMed PMID: 15456244. 9: Tarzia G, Duranti A, Tontini A, Piersanti G, Mor M, Rivara S, Plazzi PV, Park C, Kathuria S, Piomelli D. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J Med Chem. 2003 Jun 5;46(12):2352-60. PubMed PMID: 12773040.